Fibrocell Science, Inc., an autologous cell therapy company with its primary focus on developing innovative products for skin diseases and conditions, announced it has been honored with a Partners in Progress Award from the Dystrophic Epidermolysis Bullosa Research Association of America (DEBRA) for its recent work in developing potential therapies for epidermolysis bullosa (NYSE:EB), a rare, genetic connective tissue disorder for which there is presently no treatment or cure. The award was accepted by company Chairman and CEO David Pernock at the 15th Annual DEBRA of America Benefit, which took place on Oct. 24 at the Museum of Modern Art in New York City.
Fibrocell Science was recognized for its exploration of the use of genetically modified, autologous fibroblast cells for recessive dystrophic epidermolysis bullosa (RDEB), which is the most severe form of EB. This work is part of the company's exclusive channel collaboration with Intrexon Corporation to develop a treatment for RDEB.
The DEBRA of America Benefit marked the beginning of National Epidermolysis Bullosa Awareness Week, which takes place annually to increase awareness of EB, promote the need for a cure and spur advocacy initiatives on behalf of those who suffer the emotional, financial and physical burden of the disease. This year, National Epidermolysis Bullosa Awareness Week takes place Oct. 25-31.
For more information about epidermolysis bullosa, visit the DEBRA of America Web site at debra.org/whatiseb
For information about Fibrocell Science, visit fibrocellscience.com
MissionIR provides investor relations services to publicly traded companies in exchange for compensation. This article may be part of our efforts to widen a client's exposure. To read our full disclaimer, visit http://disclaimer.missionir.com